
Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug
Saniona’s drug candidate could expand Jazz Pharmaceuticals portfolio in epilepsy. But this preclinical small molecule will need to show advantages in safety and efficacy to compete with Biohaven Pharmaceuticals and Xenon Pharmaceuticals, each with clinical-stage drugs that hit the same epilepsy target. The post Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective…